# Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3

> **NCT04880395** · PHASE4 · COMPLETED · sponsor: **Fundación Huésped** · enrollment: 265 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Intervention Arm: dolutegravir/lamivudine
- **DRUG:** Comparator ARM: TDF/XTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine)

## Key facts

- **NCT ID:** NCT04880395
- **Lead sponsor:** Fundación Huésped
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-17
- **Primary completion:** 2024-05-07
- **Final completion:** 2024-05-07
- **Target enrollment:** 265 (ACTUAL)
- **Last updated:** 2025-07-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04880395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04880395, "Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04880395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*